PubRank

D M Sutton

Author PubWeight™ 21.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature. Arch Intern Med 1999 2.08
2 Pathophysiology of endotoxin shock in the primate. Am J Obstet Gynecol 1970 1.65
3 Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999 1.61
4 Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol 1979 1.42
5 Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients. Transfusion 1999 1.41
6 Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer 1996 1.11
7 High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993 1.03
8 Angioimmunoblastic lymphadenopathy: an immunochemical study. Clin Immunol Immunopathol 1976 1.02
9 Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 1994 0.90
10 Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996 0.86
11 Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995 0.86
12 The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol 1996 0.85
13 Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Br J Haematol 1998 0.83
14 Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Bone Marrow Transplant 1999 0.81
15 Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Ann Oncol 1996 0.79
16 Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange. The Canadian Apheresis Group. J Clin Apher 1997 0.78
17 Intensive plasma exchange, complement dependent microcytotoxicity and renal transplant rejection. Proc Eur Dial Transplant Assoc 1977 0.77
18 Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. Blood 1999 0.77
19 Effect of intensive plasma exchange on renal transplant rejection and serum cytotoxic antibody. Transplant Proc 1978 0.76
20 Apheresis: man versus machine. Transfusion 1997 0.76
21 Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase. Cancer Res 1984 0.75
22 A rapid tube technique for fetal cell typing. Transfusion 1979 0.75
23 Safety of therapeutic anticoagulation in patients with multiple myeloma receiving autologous stem cell transplantation. Bone Marrow Transplant 1998 0.75
24 Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program. Leuk Lymphoma 1992 0.75
25 A regional autologous bone marrow transplant network: transfers to designated centers on the day after transplant. Bone Marrow Transplant 1992 0.75
26 A controlled trial evaluating intensive plasma exchange in renal transplant recipients. Proc Eur Dial Transplant Assoc 1980 0.75
27 Central nervous system toxicity of high-dose cytosine arabinoside. Med Pediatr Oncol 1983 0.75
28 Sezary syndrome in a patient with hairy cell leukemia in remission. Cancer 1991 0.75
29 Intravascular coagulation in abruptio placentae. Am J Obstet Gynecol 1971 0.75
30 GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation. Exp Hematol 1991 0.75